The device consists of a compliant balloon at the distal end and an optical fiber that can deliver laser energy into the heart. A separate lumen is used to position device that lets the physician visualize the area under the laser gun.
Some details about the study that led to the approval:
The Approved PMA submission contained comprehensive safety and effectiveness data from the Company’s multi-center HeartLight U.S. Pivotal Clinical Study, a randomized, controlled study in which a total of 353 participants were randomized at 19 leading arrhythmia centers across the United States.
Results from the pivotal trial, an**unced at Heart Rhythm 2015, showed that when performing a single Ablation procedure using the HeartLight System, the majority of patients experienced freedom from paroxysmal AF at 12 months.* In addition, both the primary safety and efficacy endpoints were met.